Boc-D-2-溴苯丙氨酸 | 261360-76-3

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 苯丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: Boc-D-2-溴苯丙氨酸
• 中文别名: N-BOC-2-溴-D-苯丙氨酸；N-叔丁氧羰基-D-2-溴苯丙氨酸
• 英文名称: N-Boc-D-2-bromophenylalanine
• 英文别名: Boc-2-bromo-D-phenylalanine；(2R)-3-(2-bromophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• CAS: 261360-76-3
• 化学式: C₁₄H₁₈BrNO₄
• 分子量: 344.205
• InChiKey: XDJSTMCSOXSTGZ-LLVKDONJSA-N

物化性质

• 熔点：
  138.4 °C
• 沸点：
  471.3±40.0 °C(Predicted)
• 密度：
  1.5311 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  Boc-D-2-溴苯丙氨酸 在 lithium aluminium tetrahydride 、 三氟甲磺酸二丁硼 、 双氧水 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 、 N,N-二异丙基乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 10.0h， 生成 (2S,3S,4R)-4-tert-butoxycarbonylamino-5-(2'-bromophenyl)-3-hydroxy-2-methylpentanoic acid
  参考文献：
  名称：

  Deglycobleomycin A6 analogues modified in the methylvalerate moiety

  摘要：

  Previous studies have indicated that the methylvalerate subunit of bleomycin (BLM) plays an important role in facilitating DNA cleavage by BLM and deglycoBLM. Eleven methylvalerate analogues have been synthesized and incorporated into deglycoBLM congeners by the use of solid-phase synthesis. The effect of the valerate moiety in the deglycoBLM analogues has been studied by comparison with the parent deglycoBLM A(5) using supercoiled DNA relaxation and sequence-selective DNA cleavage assays. All of the deglycoBLM analogues were found to effect the relaxation of the plasmid DNA. Those analogues having aromatic C4-substituents exhibited cleavage efficiency comparable to that of deglycoBLM A(5). Some, but not all, of the deglycoBLM analogues were also capable of mediating sequence-selective DNA cleavage. (C) 2011 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2011.04.047

文献信息

• Modulators of serotonin receptors
  申请人：Wacker A. Dean

  公开号：US20050080074A1

  公开（公告）日：2005-04-14

  The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

  本发明提供了血清素受体调节剂，包含这些调节剂的药物组合物以及治疗与血清素受体调节相关的各种疾病、症状和疾患的方法，例如：代谢性疾病，包括但不限于肥胖、糖尿病、糖尿病并发症、动脉粥样硬化、糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑、抑郁、强迫症、恐慌症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；以及使用这些化合物和组合物治疗胃肠道疾病。
• [EN] MODULATORS OF SEROTONIN RECEPTORS<br/>[FR] MODULATEURS DES RECEPTEURS DE LA SEROTONINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005035533A1

  公开（公告）日：2005-04-21

  The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

  本发明提供了5-羟色胺受体调节剂、含有这种调节剂的药物组合物以及使用这些化合物和组合物治疗与5-羟色胺受体调节相关的各种疾病、病症和疾患的方法，例如：代谢性疾病，包括但不限于肥胖症、糖尿病、糖尿病并发症、动脉硬化、糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑症、抑郁症、强迫症、惊恐症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；以及使用这些化合物和组合物治疗胃肠道疾病。
• Aryl and heteroaryl compounds, compositions, and methods of use
  申请人：Mjalli M.M. Adnan

  公开号：US20050059713A1

  公开（公告）日：2005-03-17

  This invention provides aryl and heteroaryl compounds of Formula (I) as described herein, and methods of their preparation. Also provided are pharmaceutical compositions made with the compounds of Formula (I) and methods for making such compositions. Compounds of Formula (I) may be useful for treating viral infections including orthopox viruses, either alone or in combination with other therapeutic agents.

  本发明提供了公式(I)所描述的芳基和杂环芳基化合物，以及它们的制备方法。还提供了由公式(I)化合物制成的制药组合物和制备这种组合物的方法。公式(I)化合物可能有助于治疗包括正痘病毒在内的病毒感染，可以单独使用或与其他治疗剂联合使用。
• MODULATORS OF SEROTONIN RECEPTORS
  申请人：Wacker A. Dean

  公开号：US20070213337A1

  公开（公告）日：2007-09-13

  The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impaired glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

  本发明提供了5-羟色胺受体调节剂，包含这种调节剂的药物组合物以及使用这些化合物和组合物治疗与5-羟色胺受体调节相关的各种疾病、病况和障碍的方法，例如：代谢性疾病，包括但不限于肥胖症、糖尿病、糖尿病并发症、动脉粥样硬化、糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑、抑郁、强迫症、惊恐障碍、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；和使用这些化合物和组合物治疗胃肠道疾病。
• Synthesis and anti-inflammatory, analgesic activities evaluation of cimifugin amino acid ester derivatives
  作者：Hao Chen、Yan Zhao、Fangfei Liu、Jiaxin Ma、Mei Han、Jiahong Han、Enbo Cai、Limin Yang

  DOI：10.1016/j.phytol.2023.08.011

  日期：2023.10

  Cimifugin (CIM) is a chromone component of Saposhnikoviae Radix, which has good anti-inflammatory activity. In this study, 21 CIM amino acid ester derivatives were synthesized. CIM and its derivatives CIM 2, CIM 3, CIM 7, and CIM 11 have good inhibitory effects on the release of nitric oxide in lipopolysaccharide-induced mouse macrophages (RAW 264.7) inflammation model. The inhibitory effect of CIM

  Cimifugin (CIM) 是防风中的色酮成分，具有良好的抗炎活性。本研究合成了21种CIM氨基酸酯衍生物。CIM及其衍生物CIM 2、CIM 3、CIM 7、CIM 11对脂多糖诱导的小鼠巨噬细胞（RAW 264.7）炎症模型中一氧化氮的释放具有良好的抑制作用。CIM 3的抑制效果是CIM的3倍。IC 50NO抑制率分别为0.61±0.06、1.53±0.11μmol/L。CIM 3对细胞上清液中IL-1β、TNF-α和IL-6的释放也具有最好的抑制作用。CIM 3显着减轻小鼠耳肿胀，延长小鼠热痛阈，并减少体内乙酸引起的扭体次数。这些结果表明CIM 3的抗炎镇痛活性明显优于原药CIM。